Recalls / Class II
Class IID-1637-2019
Product
Avastin, 25MG/ML Syringe, [a) 0.1 mL NDC 70731-0197-91; b) 0.12 mL NDC 70731-0197-92; c) 0.15 mL NDC 70731-0197-93] per vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701.
- Affected lot / code info
- All lots within expiry
Why it was recalled
Lack of Assurance of Sterility
Recalling firm
- Firm
- RXQ Compounding LLC
- Notification channel
- Press Release
- Type
- Voluntary: Firm initiated
- Address
- 340 W State St Unit 9, N/A, Athens, Ohio 45701-1564
Distribution
- Quantity
- N/A
- Distribution pattern
- Nationwide USA
Timeline
- Recall initiated
- 2019-06-19
- FDA classified
- 2019-08-08
- Posted by FDA
- 2019-08-14
- Terminated
- 2022-09-16
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-1637-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.